DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
25 hedge funds and large institutions have $179K invested in DMK Pharmaceuticals Corporation Common Stock in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
14% more funds holding
Funds holding: 22 → 25 (+3)
35% less capital invested
Capital invested by funds: $276K → $179K (-$97.7K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$44.9K |
| 2 |
JP Morgan Chase
New York
|
+$42.2K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$38K |
| 4 |
VF
Virtu Financial
New York
|
+$23.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$21.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$32.9K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.05K |
| 3 |
FCMT
Founders Capital Management (Texas)
Houston,
Texas
|
-$171 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$120 |
| 5 |
Morgan Stanley
New York
|
-$23 |
DMK Hedge Fund Activity: Q3 2023 in Review
25 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2023, worth a combined $179K — down 35% from $276K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DMK positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $44.9K. The largest seller was Cubist Systematic Strategies, exiting entirely with an estimated $32.9K sold.
- 25 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2023, up from 22 in Q2 2023.
- Funds reported $179K of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2023, down 35% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2023 and 2 closed out, a net change of +4 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2023 was Geode Capital Management, an estimated $44.9K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2023 was Cubist Systematic Strategies, an estimated $32.9K sold.
Based on aggregated 13F filings for Q3 2023.